Zimbabwe has declined a major US healthcare agreement worth 367 million US dollars (£272m) over five years because of Washington's request for sensitive biological samples.
This move was revealed following a government memo from December was leaked, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
A government spokesman has since explained that the US was demanding access to health data for research and commercial purposes while refused to guarantee the benefits from any future treatments.
"We are forced to start the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the United States had provided over $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has appealed for continued dialogue to find a agreement acceptable to all parties so the country's vital HIV programme can continue.
Broader Implications
This development follows a comparable situation in neighbouring Kenya, where a high court blocked a similar deal with the US following concerns were filed about the security of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has slashed overseas assistance and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the US government, but Trump argued its spending was "wasteful" and his administration was seeking direct bilateral agreements to enhance transparency and responsibility.
Based on reports, 16 African countries have so far agreed to similar agreements, constituting more than $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration might have yielded extraordinary advantages for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment via US-supported programmes," the Ambassador said.
However, official spokesman Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, without any corresponding promise of access to any medical innovations – like new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our nation would provide the raw materials for medical research without any assurance that the resulting innovations would be accessible to our population if a new health crisis arise."
Sovereignty and International Frameworks
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one deals were undermining systems previously set up via the global organization.
The spokesperson cited its Pandemic Benefit-Sharing system designed to deal with potential global health emergencies.
"This framework is designed to guarantee that when a country provides its data, the benefits – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the capability to develop them."
These objections regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We welcome further discussions with our American counterparts on how subsequent co-operation might be designed in a way that honours the sovereignty and dignity of both nations."
Medical Community Reaction
Medical experts stated it acknowledged the government's concerns, but recommended that talks must proceed given that a large portion of the country's Aids initiatives relied on external financing.
"Where technical issues arise, such as those involving information security or implementation frameworks, these can frequently be addressed via detailed discussion and negotiated safeguards," the group said.
The situation underscores the ongoing tensions between receiving vital international aid and safeguarding national sovereignty in an increasingly data-driven world.